Long-term adjunctive lacosamide treatment in patients with partial-onset seizures

Grants

Funding Acknowledgements

The authors acknowledge Anthony Daniels, UCB Pharma, Raleigh, NC, USA, and Maria-Luise Esch, UCB Pharma, Monheim am Rhein, Germany, for clinical project management, and Jennifer Hepker, PhD of PMCG, Chicago, IL, USA, and Steve Dobson of Evidence Scientific Solutions, Horsham, UK, for writing support, which was funded by UCB Pharma.